Stem cells are the body's ultimate shape-shifters, sustaining tissues by balancing two competing demands: maintaining their ...

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen receptor T-cell therapies in autoimmune and rheumatic diseases.“It is quite ...

Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) this week outlined progress in its battery technology development and an expanded ...

He suggested taking time to understand the codes and standards in NFPA 855, “Standard for the Installation of Stationary ...

We look at the benefits and potential issues with plug-in solar, including how it works and the regulatory changes needed.

Growing antimicrobial resistance is prompting renewed interest in phage therapy, with preliminary data indicating improved outcomes when combined with standard antibiotics.

ONCY READ THE FULL ONCY RESEARCH REPORT We are initiating coverage of Oncolytics Biotech (NASDAQ: ONCY) with a valuation of $6.00. Oncolytics is a clinical-stage immuno-oncology company advancing ...

Fred Hutch at AACR: Colorectal cancer and glyphosate exposure, potential therapeutic targets for ovarian cancer, a new molecular standard of care for cancer patients — and more ...

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Stocks Under $10 to Buy and Hold Forever. On March 27, Nuvation Bio Inc.

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...